|Articles|September 1, 2018
- Pharmaceutical Executive-09-01-2018
- Volume 38
- Issue 9
Pharmaceutical Executive, September 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 7 years ago
Paul Perreault: The Global CEOover 7 years ago
Specialty Pharma’s Move to Mainstreamover 7 years ago
Specialty Product Launch Insightsover 7 years ago
Beyond Big Data: Meeting the Specialty Marketing Challengeover 7 years ago
Specialty Focus: Tackling Rare Mutation in CFover 7 years ago
The ‘Spare-No-Expense’ Alternativeover 7 years ago
Pharm Exec's 17th Annual Industry Auditover 7 years ago
Specialty Supply Chain Decisionsalmost 8 years ago
FDA Struggles to Advance Biosimilarsalmost 8 years ago
Country Report: UKAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg
5